Event Report: From Micro-Evolution to Macro-Waves
This page reorganizes the January 31 event content for clarity and readability. Use the tabs below to switch between Naoya Nishiyama's talk (infectious diseases / bacterial evolution) and Takuya Miyashita's talk (tsunami engineering / disaster mitigation).
Naoya Nishiyama (Infectious Disease Physician / Researcher)
Theme: Pneumonia, Pseudomonas Evolution, and the Fight Against Antimicrobial Resistance
This talk connected frontline clinical infectious disease practice with basic microbiology research, spanning from real pneumonia cases to adaptive evolution in Pseudomonas. It reframed the everyday question, “Why must we complete an antibiotic course?” through the lens of AMR and evolutionary biology.
🩺 Clinical Entry: Pneumonia Is a Close and Serious Risk
Using a case of a 30-year-old man, Nishiyama showed how CT can reveal pneumonia not clearly visible on plain X-ray, and emphasized that even younger adults can worsen when immune balance is disrupted.
Why Finishing Antibiotics Matters
- Prevent relapse: stopping early can allow infection to rebound.
- Reduce resistance pressure: incomplete courses can promote AMR selection.
Multi-Layer Human Defense System
Invading microbes are removed step by step through the following defense layers.
1. Nose/Mouth (Physical Barrier)
Traps foreign particles at the entry and lowers lower-airway invasion.
2. Pharynx/Tonsils (Capture)
Lymphoid tissues in the throat capture microbes and provide local defense.
3. Bronchi (Ciliary Clearance)
Mucus and ciliary motion move foreign material upward, limiting lung reach.
4. Alveoli (Macrophages)
Immune cells phagocytose and process microbes that reach deep lung tissue.
Smoking particularly impairs ciliary clearance, increasing pneumonia risk.
Evolutionary Trade-Offs in Pseudomonas
Comparison of Wild-Type (Offensive) vs Adapted-Type (Defensive)
Wild Type
Highly motile and toxin-producing, dominant in early acute infection but more visible to host immunity and antibiotics.
During adaptation, bacteria reduce motility and toxin output while strengthening resistance and biofilm formation for long-term persistence.
Details
Open Full Text
Naoya Nishiyama (Infectious Disease Physician / Researcher) Theme: Pneumonia, Pseudomonas Evolution, and the Fight Against AMR 1. Background and Career Path Nishiyama graduated from the University of the Ryukyus School of Medicine and spent about ten years in clinical practice. His specialty is infectious diseases, with practical work in infection control and antimicrobial stewardship in hospital settings. His team monitored resistant organisms, reviewed antibiotic prescriptions, and intervened when treatment optimization was needed. He is currently conducting basic research at the University of Washington Department of Microbiology, focusing on Pseudomonas evolution. 2. Pneumonia as a Real-World Threat A clinical case of a 30-year-old man with fever and chest pain was presented. Plain X-ray findings were subtle, but CT clearly identified left-sided pneumonia. This illustrated that even younger, generally healthy adults can develop serious pneumonia when host defense is disrupted. In Japan, pneumonia remains one of the major causes of death, despite changes in reporting categories over time. Why should patients finish prescribed antibiotics? Common question: “Can I stop once symptoms improve?” Nishiyama’s answer was clear: no. Risk of relapse: stopping too early can leave viable bacteria and trigger recurrence. Risk of resistance: incomplete treatment can increase selective pressure for antimicrobial resistance. Following dose and duration is important for both personal recovery and public AMR control. 3. Pneumococcus and Multi-Layer Host Defense The most common cause of community-acquired bacterial pneumonia is Streptococcus pneumoniae. Pneumococcus has a capsule that helps it evade phagocytosis and increases virulence. The classic Griffith experiment was discussed as an example of bacterial adaptation through genetic transformation. Multi-layer human defense system: Physical barrier: nasal hair and saliva reduce microbial entry. Tonsillar tissue: lymphoid structures in the throat capture invading organisms. Ciliary clearance: bronchial cilia and mucus transport particles upward toward the mouth. Alveolar macrophages: immune cells in distal lungs phagocytose bacteria that pass earlier barriers. Pneumonia develops when this defense system weakens relative to pathogen pressure. Smoking is a key risk factor because it impairs ciliary function and raises pneumonia risk. 4. Pseudomonas as a Difficult Nosocomial Pathogen Pseudomonas aeruginosa is widely present in environmental water and soil. It is often low-virulence in healthy hosts, but can become life-threatening in vulnerable patients. It is intrinsically difficult to treat because many antibiotics are less effective. It also thrives in moist environments and can colonize medical devices. Why does it spread in healthcare settings? Poorly maintained humidifiers or nebulizers can become reservoirs. The organism forms biofilms on devices such as ventilator tubing and catheters. Inside biofilm communities, bacteria are more protected from both antibiotics and host immunity. 5. Evolutionary Adaptation in Chronic Infection Early or environmental strains are often motile and toxin-producing (“wild type” behavior). During chronic airway disease, long-term lung colonization selects for adapted phenotypes. These adapted populations tend to show: Increased diversity within one patient. Reduced motility. Reduced toxin production. Slower growth. Enhanced biofilm/mucoid behavior. This shift reflects strong in-lung environmental stress: immune pressure, antimicrobial exposure, inflammation-related tissue damage, oxygen limitation, and nutrient limitation. In such conditions, strains with lower offensive traits but stronger persistence traits are favored by natural selection. Nishiyama’s research asks why slower-growing, less overtly virulent phenotypes are repeatedly selected in lungs. Approaches include experimental evolution, genome analysis, and game-theory-based interpretation. Understanding this process may enable therapies that not only kill bacteria, but also constrain maladaptive evolution and chronicity.
